cse: neon · 2021. 2. 4. · on may 21, 2020, mind medicine (mindmed) inc. announced that it had...
TRANSCRIPT
-
neonmindbiosciences.comneonmindbiosciences.comCSE: NEON • OTC: NMDBF • FRA: 6UF
DEVELOPING INNOVATIVE TREATMENTS AND PRODUCTS TO TACKLE OBESITY AND PROMOTE HEALTH & WELLNESS
-
This presentation contains "forward looking information" within the meaning of applicable Canadian securities legislation. Wherever possible, words such as "plans", "expects", or "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, have been used to identify forward looking information.
Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of NeonMind Biosciences Inc. (“NeonMind”, “us” “we”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of our management made in light of their experience and their perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Management believes that the assumptions and expectations reflected in such forward looking statements are reasonable.
FORWARD LOOKING INFORMATION
CSE: NEON • OTC: NMDBF | 2
-
3
NeonMind Biosciences is an integrated psychedelic drug development and wellness company focused on therapeutics uses of psychedelics to address public health needs including obesity, weight management and mental health
INVESTMENT HIGHLIGHTS• Focused on psychedelic drug development program within unique
indication – obesity and weight management
• Positive Pre-Clinical data supports pursuit of two parallel development tracks: low dose and high dose psilocybin therapeutics
• Establishing NeonMind-branded specialty mental health clinics to capitalize on psychedelic-based treatments for mental health disorders
• Near-term revenue opportunities with exciting consumer product launches in high growth functional food markets
• Led by seasoned management team with expertise in establishing access and adoption of novel treatments including drug development and commercial deployment
CSE: NEON • OTC: NMDBF | 3
-
4
NEONMIND AT A GLANCE
CSE: NEON • OTC: NMDBF | 4
PSYCHEDELIC RESEARCH DIVISION
●Proprietary asset; only player in massive unaddressed medical need
●Engaged in drug development research for the potential therapeutic uses of psychedelic compounds
●Advancing two psilocybin drug development programs targeting obesity
●Extensive US and international patent applications pending, covering the spectrum of weight management conditions
MEDICAL SERVICES DIVISION
● Early exposure to high growth transformational medical market
● Expected to announce initial NeonMind-branded specialty mental health clinics in Canada in 2021
● Integrated services platform to deliver evidence-backed, innovative treatments for mental health tailored to local market needs
● Enabling NeonMind to capture the potential success of the growing pipeline of psychedelic-based therapeutics across the mental health industry
CONSUMER PRODUCTS DIVISION
● Stable, near-term existing market
● Using proprietary formulations to develop and commercialize functional food products infused with non-psychoactive mushrooms
● Initial launch in Canadian market, introducing select e-commerce offerings in the U.S.
● Global rights holder to a robust catalogue of functional mushroom formulations to promote health and wellness
-
5
MARKET OPPORTUNITY – GLOBAL DEMAND FOR WEIGHT MANAGEMENT IS MASSIVE
1. WHO 2020, Obesity and Overweight. 2. Research and Markets 2017. 3. Novo Nordisk investor presentations. 4. FDA Drug Database. 5. Evaluate Vantage 2020.
MASSIVE GLOBAL MARKET FOR WEIGHT MANAGEMENT2
WEIGHT MANAGEMENT CONTINUES TO BE A GLOBAL HEALTH ISSUE1
LIMITED OPTIONS AND PAUCITY OF INNOVATION4,5
VS
CSE: NEON • OTC: NMDBF | 5
13% of Adults Considered Obese
1.9BOverweight
650MObese US $245B by 2022
Estimated Annual Spend on Products and Services
31% CAGRGlobal Anti-Obesity
Drug Market
7% CAGRGlobal Weight
Management Market
Only 5 Drugs ApprovedFor Long-term use in the US
Only 1 Drug Candidate in Phase 3
STRONG GROWTH TRENDS IN ANTI-OBESITY DRUG MARKET: OUTPACING OVERALL MARKET2,3
-
6
WE ARE FOCUSED ON DEVELOPING PSYCHEDELIC-BASED THERAPEUTICS TO TREAT OBESITY
● We are one of two companies working on developing psilocybin into a prescription drug for weight management
● Patent portfolio provides protection for therapeutic use of psilocybin and derivatives for weight management
● Preclinical data to support drug development and bolster patent portfolio
● Management experience in drug development and commercialization
ObesityNeurology
Addiction
Psychiatry
PSYCHEDELIC RESEARCH DIVISION
CSE: NEON • OTC: NMDBF | 6
-
7
CURRENT OPTIONS ARE NOT SUFFICIENT - PSYCHEDELICS OFFER A NEW OPPORTUNITY
PharmacotherapyAvg. 4% to 9% weight loss
Bariatric SurgeryAvg. 13% - 40% weight loss5
1. Apovian 2015, JCEM. 2. Wharton 2020, CMAJ. 3. Data from pivotal clinical studies of FDA approved anti-obesity drugs. 4. Lemstra 2016, Patient Pref Adherence. 5. Maciejewski 2017, JAMA Surg.
OBESITY TREATMENT REQUIRES A MULTIMODAL APPROACH1,2
01
02
WEIGHT LOSS IS NOT EASYAND EFFICACY IS LOW3,4
PSYCHEDELICS MAY ENHANCE TREATMENT MODALITIES
Psychological and Behavioral Therapy
Psychological and Behavioral Therapy
Pharmacotherapy
30% Drop OutWeight Regain is a Major Issue
Only 4 – 9% Weight LossPharmacotherapy with Diet and Exercise
Fundamental to treatment are lifestyle changes evoked by psychological and behavioral therapy
Diet and ExerciseAvg. 0% to 6% weight loss
CSE: NEON • OTC: NMDBF | 7
-
8
PURSUING TWO TREATMENT PATHS SUPPORTED BY REPUTABLE SCIENTIFIC EVIDENCE
• Product Candidate: low dose psilocybin
• MOA: target 5-HT2C receptor to induce satiety without hallucinogenic effects
• Use: routinely to mitigate appetite throughout the program
• Treatment Delivery: physician prescription and pharmacy dispensing
• Clear Clinical Pathway: FDA guidance document on “Developing Products for Weight Management”5
• Supportive Pre-Clinical Data: NeonMind’s proprietary animal data supports psilocybin in reducing weight gain
TRADITIONAL DRUG THERAPY
• Product Candidate: high dose psilocybin
• MOA: target 5-HT2A receptor to induce hallucinogenic effect
• Use: during psychotherapy sessions using proprietary treatment protocol to induce lasting lifestyle changes
• Treatment Delivery: in-clinic, overseen by health professionals
• Building On Longstanding Practice to Enhance Results: Psychotherapy is routine and fundamental to weight management treatment
• Promising New Treatment Modality Enhancement1,2,3: Favorable DEP study results from renowned groups recognized by regulatory bodies with Breakthrough Designation
DRUG ENHANCED PSYCHOTHERAPY (DEP)
1. Davis 2020, JAMA Network. 2. Kaertner 2021, Sci Rep. 3. Smigielski 2019, Sci Rep. 4. Kumar 2015, Obesity. 5. FDA 2018, Developing Products for Weight Management Rev1. CSE: NEON • OTC: NMDBF | 8
-
9
PSILOCYBIN: MULTIFACETED MOLECULE WITH MULTIPLE OPPORTUNITIES TO ADDRESS OBESITY
Psilocybin1(and derivatives)
5-HT2A Receptor 5-HT2C Receptor
• Involved in hallucinogenic effect of psychedelics
• Drug target in exciting field of drug enhanced psychotherapy (DEP) to treat cognitive behavioral disorders including eating disorders2,3
• Involved in appetite control; when engaged induces an anorectic effect causing a loss of appetite
• Drug target of previous FDA approved prescription drug for obesity
1. Nichols 2016, Pharmacol Rev. 2. Reiff 2020, Am J Psychiatry. 3. Vollenweider 2020, Nat Rev Neurosci. CSE: NEON • OTC: NMDBF | 9
-
10
NEONMIND’S PROPRIETARY ANIMAL DATA SUPPORTS PSILOCYBIN EFFICACY IN REDUCING WEIGHT GAIN
• Psilocybin reduced weight gain by 31 and 28% for low and high dose respectively relative to placebo
• Significant reduction in weight gain was seen by day 3 for high dose and day 4 for low dose
• Novel data bolsters patent applications
● Method: Male rats were fed unlimited high calorie diet for 5 days with randomization to low dose (5mg/kg)(n=7) or high dose (20 mg/kg) (n=7) or placebo(n=12) on day one. Rats were weighed daily to measure weight gain.
CSE: NEON • OTC: NMDBF | 10
Cumulative Weight Gain (from beginning of study)
1. Data on file NeonMind Biosciences
-
11
Formulation Indication MOA Preclinical Phase I Phase 2 Phase 3 Ongoing Work Next Milestone IP
High Dose Psilocybin
Drug Enhanced Psychotherapy
Weight Management 5-HT2A
Regulatory Package
Design of Phase 2 ProtocolPre-IND
US Provisional and PCT
Applications Filed
Low Dose Psilocybin
Drug Therapy
Weight Management
5-HT2CRegulatory Package
Animal Studies Pre-IND
US Provisional and PCT
Applications Filed
DEVELOPMENT PIPELINE
Program Development Stage Status
Our two psilocybin-based drug candidates focus on treating obesity and weight management
CSE: NEON • OTC: NMDBF | 11
-
12
IP PORTFOLIO SURROUNDS THE SPECTRUM OF WEIGHT MANAGEMENT CONDITIONS• Global patent portfolio with potential
rights in 152 countries including the US
• 11 US provisional and 4 PCT applications filed to date
• Claims covering methods of treating obesity and weight management conditions
• R&D activities will support additional applications with at least 5 planned
• Anticipated Protection Expiry: 2041
Psilocin*, Psilocybin*
4-SH-dimethyltryptamine*
1-methylpsilocin*
4-fluoro-N,N-dimethyltryptamine*
O-acetylpsilocin
4-hydroxy-N-methyl-N-isopropyltryptamine*
4-hydroxy-N-methyl-N-ethyltryptamine*
LSD**, LSA**, DMT**
COMPOUNDS COVERED
Aiding Weight Loss
Obesity
Compulsive Eating Disorder
Diet Alteration
Reduction of Food Cravings
Decreasing Food Intake
Complications Associated with Obesity
TREATMENTS COVERED
* NeonMind owns 100% of intellectual property** NeonMind owns 80% of intellectual property, Translational Life Sciences Inc. (research collaborator) owns remaining 20%
CSE: NEON • OTC: NMDBF | 12
-
13
GROWING DEMAND FOR MENTAL HEALTH TREATMENTS AND SPECIALTY MENTAL HEALTH CLINICS
MENTAL HEALTH CONDITIONS CONTINUE TO BE A GLOBAL HEALTH ISSUE
STRONG GROWTH TRENDS IN MENTAL DISORDER TREATMENT MARKET2
MASSIVE GLOBAL MARKET FOR GLOBAL MENTAL DISORDER TREATMENT2
284MAnxiety, PTSD
264MDepression
Global Population of Affected Individuals1
1. Ritchie 2018, Our World in Data. 2. Coherent Market Insights, 2020. Mental Disorder Treatment Market Analysis. 3. Estimates from company marketing materials. Assumes average patient completes treatment program with 6 drug sessions and will be treated annually.
US $48.8B by 2022
6.6% CAGRForecast period
(2020-2027)
MEDICALSERVICES DIVISION
CSE: NEON • OTC: NMDBF | 13
-
14
PSYCHEDELICS HAVE POTENTIAL TO ADDRESS LARGE MEDICAL NEED BUT REQUIRE SPECIALIZED TREATMENT INFRASTRUCTURE
PSYCHEDELIC DRUG DEVELOMENT PROGRAMS ARE NEARING APPROVAL1
Psychedelic Indication Est. Approval
MDMA PTSD 2023+
Psilocybin TRD 2025+
Psilocybin MDD 2025+
1. Company marketing materials and management estimates.
PSYCHEDELIC TREATMENTS WILL REQUIRE SPECIALIZED CLINICS INFRASTRUCTURE
● Psychedelics will require administration under direct supervision in a controlled setting
● Clinics infrastructure buildout still in infancy
● Opportunity for NeonMind to take leadership in specialized clinics providing psychedelic treatments
MEDICALSERVICES DIVISION
CSE: NEON • OTC: NMDBF | 14
-
15
• Establishing NeonMind-branded specialty mental health clinics in underserved markets; first clinic expected to be announced in 2021
• Incorporating evidence-backed innovative treatments for a variety of mental health needs, including psychedelic treatment modalities
• Assembling a team of experts to become the trusted partner for specialty mental treatments
• Establishing a strategic footprint with early-mover advantage
• Positioned to capitalize on the large and promising pipeline of the new psychedelic therapies, once approved
LAYING THE FOUNDATIONS TO BE THE TRUSTED PARTNER IN TRANSFORMATIONAL MENTAL HEALTH TREATMENTS
MEDICALSERVICES DIVISION
CSE: NEON • OTC: NMDBF | 15
-
NEAR-TERM COMMERCIALIZATIONLeveraging existing proprietary functional food formulations to sell direct-to-consumer on our e-commerce platform.
Initial sales recognized for mushroom-infused coffee products in Canada; plan to launch e-commerce platform in the U.S.
Capturing a segment of global functional mushroom market- forecasted to reach $34.3 billion by 2024*.
CSE: NEON •OTC: NMDBF | 16
https://www.mordorintelligence.com/industry-reports/functional-mushroom-market*NDP food study, “U.S. Consumers’ Desire to Use Food as Medicine is Evidenced by Emerging Superfoods”
CONSUMER PRODUCTS DIVISION
https://www.mordorintelligence.com/industry-reports/functional-mushroom-markethttps://www.npd.com/wps/portal/npd/us/news/press-releases/2019/us-consumers-desire-to-use-food-as-medicine-is-evidenced-by-emerging-superfoods/https://www.npd.com/wps/portal/npd/us/news/press-releases/2019/us-consumers-desire-to-use-food-as-medicine-is-evidenced-by-emerging-superfoods/
-
PRODUCT OFFERINGS
CSE: NEON • OTC: NMDBF | 17
Our range of coffee products are infused with legal medicinal mushrooms such as Lion’s Mane, Turkey Tail, Reishi and Cordyceps.
CONSUMER PRODUCTS DIVISION
-
PROGRESS AND KEY ACHIEVEMENTS
CSE: NEON • FRA: UF6 | 18CSE: NEON • OTC; NMDBF | 18
Established international and US patent applications covering the spectrum of weight management conditions
Pre-clinical study completed demonstrating weight sparing signal for low and high dose-psilocybin regime - 4Q20
Canadian eCommerce launch of four functional mushroom coffee blends for consumer division – 4Q20
Filed four (4) NHP applications with Health Canada to support the launch of consumer products division - 1Q21
US $4.6M raised in January 2021 IPO – 1Q21
Established Medical Services Division to launch NeonMind-branded specialty mental health clinics - 2Q21
-
19
UPCOMING MILESTONES
CSE: NEON • FRA: 6UF | 19
NeonMind expects to execute on the following key initiatives:● Finalize integrated drug development plan to
define research plan needed to advance both programs through to NDA – 2Q21
● E-commerce U.S. launch – 2Q21
● Preclinical study #2 data: – 3Q21
● Pre-IND meeting with FDA – 4Q21
● Complete design of Phase 2a study with FPI – 4Q21/1Q22
● Launch inaugural NeonMind-branded Specialty Clinic for mental health – 1Q22
-
MANAGEM
ENT & CONSULTANTS
ROBERT TESSAROLOPRESIDENT & CHIEF EXECUTIVE OFFICER
● Over 25 years of experience in the pharmaceutical industry● Former President, CEO and Director of Mind Medicine Inc.
(NEO:MMED)● Former President & CEO of Cipher Pharmaceuticals Inc.
(TSX:CPH)● Former VP, General Manager Celgene US Inflammation &
Immunology and former President Watson Pharmaceuticals Canada
CSE: NEON • OTC: NMDBF | 20
TREVOR MILLARCHIEF PSYCHEDELIC OFFICER
● Social-entrepreneur advancing the psychedelic movement since 2013
● Board Chairman Multidisciplinary Association of Psychedelic Studies (MAPS) Canada
● Co-Founder and Board Member Canadian Psychedelic Association.
● Founder of Liberty Root Therapy Inc.; featured in the award-winning psychedelic documentary 'DOSED'
RICK HUANGCFO
● CFO of Better Plant Sciences Inc. (CSE: PLNT)● Serves as Chair of the Audit Committee for Datable
Technology Corp. (TSXV: TTM)● Former CFO of Hanwei Energy Services Corp. (TSX: HE)● Former Chair of Governance and member of Audit
Committees at Poydras Gaming Finance Corp. (TSXV: PYD)
CLIVE WARD-ABLEMEDICAL & SCIENTIFIC AFFAIRS CONSULTANT
● Physician and a pharmacist who has worked in the pharmaceutical industry for over 28 years
● Has worked in large and small pharmaceutical and biotechnology companies in Canada, the U.S., UK, Switzerland, and South Africa
● Currently a member of the Board of Directors for Clinical Trials Ontario
● Former member of the Medical & Scientific Advisory Committee of Innovative Medicines Canada.
ERNIE HOVP, CORPORATE DEVELOPMENT
● Over 14 years of development and commercialization
experience in the biopharma and diagnostics industry
● Experience throughout value chain from pre-clinical to
product management
● Success in corporate development including licensing,
M&A, and capital raise
● PhD from Western University
PHILIPPE MARTINDRUG DEVELOPMENT CONSULTANT
● 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology and neurology.
● Chief of Clinical Development & Operations at BioAtla, Inc.,
● Former Corporate Vice President at Celgene
-
ADVISORS DR. WILLIAM PANENKAMEMBER, ADVISORY BOARD
● Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.
● Founder and Director, Translational Life Sciences Inc.
CSE: NEON • OTC: NMDBF | 21
DR LAIRD BIRMINGHAMMEMBER, ADVISORY BOARD
● World renowned eating disorder specialist for over 35 years, who has pioneered several new internationally recognized treatments for eating disorders
● Professor at the University of British Columbia, Faculty of Medicine Department of Psychiatry
DR. FRANK RUSSOMEMBER, ADVISORY BOARD
● Professor of Psychology at Ryerson University, Hear the World Research Chair in Music and Emotional Speech.
● Affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), and adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC).
● Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association
CHARLES BOULAKIAMEMBER, ADVISORY BOARD
● Over 18 years of experience as a patent lawyer in the preparation and prosecution of patent applications
● Partner of Ridout & Maybee LLP ; practice focus directed towards the preparation and prosecution of patent applications in the biotechnology, chemistry, biofuel, oil and gas and pharmaceutical areas
● Vice-Chair of the AIPPI Standing Committee on Pharma and Biotechnology
DR. ALASDAIR BARRPRINCIPAL INVESTIGATOR
● PhD in Neuropharmacology, post doctoral training at Scripps Institute and drug discovery with Novartis.
● Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, UBC
● Approved by Health Canada to possess psilocybin for NeonMind Preclinical trial
DR. GARCIA-ROMEUMEMBER,ADVISORY BOARD
● Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine.
● Has conducted more than 90 high-dose psilocybin sessions in the laboratory since 2012
● Founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research.
-
BOARD OF DIRECTORS
CSE: NEON • OTC: NMDBF | 22
PENNY WHITEEXECUTIVE CHAIRMAN, DIRECTOR, FOUNDER
● Serial entrepreneur with over two decades of experience building companies.
● Recognized in PROFIT Magazine's W100● Co-founder, President and CEO of Better Plant Sciences
Inc. (CSE: PLNT, OTCQB:VEGGF)● Former Director Merus Labs Inc. (TSX:MSL)
JEFF B. SMITHINDEPENDENT DIRECTOR
● Over 30 years of general management experience
● Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies (NYSE:JNJ)
● Co-Founder and CEO of Paragon Vitamins and
● Co-Founder & Partner at Ignite Ventures Studios
KARI RICHARDSONINDEPENDENT DIRECTOR
● Over 15 years practicing as a securities lawyer● Partner of Owen Bird Law; practice focused on mergers
and acquisitions, corporate finance and securities.● Member of the Law Society of New Brunswick since
1997 and a member of the Law Society of British Columbia since 2005.
-
CAPITAL STRUCTURE
Total Issued and outstanding Shares: 123,127,983
Shares held by Insiders: 58,861,500
Shares subject to Escrow: 46,542,1501
Equity Incentives issued (Options & RSUs): 24,625,597
Average daily trading volume in Canada: 1,019,1492
(1) Shares have been escrowed as required by NI 46-201 Escrow for Initial Public Offerings; released in tranches beginning one month after the Listing Date and ending 3 years after the Listing Date.
(2) As of the close of business on May 28, 2021.
STOCK AND FINANCIAL INFORMATION
CSE: NEON • OTCQB: NMDBF | 23
CASH POSITION
1 As of March 31, 2021.
2 Gross burn rate based on the internal 2021 Budget Plan, excluding anticipated sales from consumer products and unscheduled R&D expenses.
Cash, cash equivalent and short-term investments position of $2.7M1 as of March 31.
Estimated monthly burn rate of $350,0002
-
24
INVESTMENT SUMMARY❖ Focused on psychedelic drug development program within unique
indication – obesity and weight management
❖ Pre-clinical data supports pursuit of two parallel development tracks: low dose and high dose psilocybin therapeutics
❖ Establishing NeonMind-branded specialty mental health clinics to capitalize on psychedelic-based treatments for mental health disorders
❖ Near-term revenue opportunities with exciting consumer product launches in high growth functional food markets
❖ Led by seasoned management team with expertise in pharmaceuticals, drug development and commercialization
CSE: NEON • OTC: NMDBF | 24
-
CONTACT
ROB TESSAROLOPresident &
Chief Executive [email protected] +1 416 919 9483
PENNY WHITEExecutive Chairman, Founder & Director
[email protected] +1 604 617 7979
CSE: NEON • OTC: NMDBF | 25
-
APPENDIX
CSE: NEON • OTC: NMDBF | 26
-
27
RESURGENCE IN PSYCHEDELICMEDICINE IS JUST BEGINNING● Resurgence in clinical psychedelic use enabled by more
progressive regulatory framework
● Growth in clinical studies, in particularly psilocybin1
● Regulators recognize clinical value, granting Fast Track, Breakthrough Therapy, and Priority Review
● Recent FDA approval of SPRAVATO® (esketamine) for treatment-resistant depression○ Est. > US$1B in peak sales2
● Big Pharma’s interest and involvement:○ J&J (esketamine), AbbVie (rapastinel)
BREAKTHROUGH THERAPY
Esketamine Rapastinel MDMA Psilocybin
MDMAPsilocybin
1. Tullis 2021, Nature News. 2. FiercePharma 2019.
Clinical Trials in Psychiatric, Addiction, and Eating Disorders1
CSE: NEON • OTC: NMDBF | 27
-
28
SURGE IN COMPANIES CAPITALIZING ON PSYCHEDELICS WITH STRONG SUPPORT FROM INVESTMENT COMMUNITY● 15+ public companies totaling over US$5.0B in market cap involved in psychedelics1
● 200% market cap growth over past year2,3
● Over US$700.0M in capital raised in last 12 months4
● Company formation has occurred throughout psychedelic value chain
1. Horizons Psychedelic Stock Index ETF (PSYK) for list of top companies. 2. Since H2 2020. 3.Company filings. 4. As of Feb 19, 2021.
CONTRACT MANUFACTURING DRUG DEVELOPMENT MEDICAL CLINIC CONSUMER/ WELLNESS
CSE: NEON • OTC: NMDBF | 28
-
29
EFFECTIVE OPTIONS ARE STILL NEEDEDTO ADDRESS THE OBESITY EPIDEMIC
1.Blumenthal 2018 Commonwealth Fund. 2. CDC Oct 2013, Prevalence of Obesity Among Adults. 3. Masters 2013, Am J Public Health. 4. Finkelstein 2009, Health Aff. 5. American Society for Metabolic and Bariatric Surgery 2020.
Percentage of Adult Population Considered Obese1
GROWING US PUBLIC HEALTH CRISIS 2,3 MASSIVE COST TO SOCIETY4 MAJOR UNMET NEED
Estimate of US Bariatric Surgeries5
300,000
250,000
200,000
150,000
100,000
50,000
0
2011 2012 2013 2014 2015 2016 2017 2018
252,000
20% > $140B USEstimated Annual Spend on Obesity-related Medical Care
Despite Current Options, Bariatric Surgeries Continue to Rise5of Adult Deaths Associated to being Overweight or Obese
of Adults are Obese35%
CSE: NEON • OTC: NMDBF | 29
-
30
OBESITY: MUCH MORE THAN JUST EXCESS WEIGHTObesity tied to many comorbidities1 such as: • Type 2 diabetes, metabolic syndrome, gallbladder disease• Hyperlipidemia, hypertension, cardiovascular disease,
non-alcoholic fatty liver disease, • Osteoarthritis• Cancer
Associated with mental health disorders: • Depression, anxiety, PTSD, OCD
People living with obesity face substantial bias and stigma
1. Wharton et al. 2020, Canadian Adult Obesity Clinical Practice Guidelines. 2. Xu 2018, JAMA Netw Open. 3. Apple 2018, Obes Sci Pract.
“There is a recognition that obesity management should beabout improved health and well-being, and not just weight loss”From Canadian Obesity Clinical Practice Guidelines 2020
SURVIVAL CURVE FOR DIFFERENT BMI CLASSES2,3
CSE: NEON • OTC: NMDBF | 30
-
31
DURABLE EFFICACY IS LACKING
Weight Loss from Drug Therapy Consistently Hits a Plateau within a Year
Oftentimes Weight Loss Stops With Discontinuation of Drug Therapy and Weight Gain Can Occur While on Drug Therapy
Pi-Sunyer 2015, NEJM. Wadden 2021, JAMA Network. Davidson 1999 JAMA.CSE: NEON • OTC: NMDBF | 31
-
32
LOW PERSISTENCE OF USE IN REAL WORLD ALSO DIMINISHES EFFICACY• Saxenda is one of the more efficacious drugs
• Despite this, persistent use dramatically decreases over time
• Less than 10% stay on after one year
• Even with a patient support program, persistent use drops significantly
• Similar findings are seen with other drugs
Wharton 2020, Obes Sci Pract. CSE: NEON • OTC: NMDBF | 32
-
R&D COLLABORATIONSTRANSLATIONAL LIFE SCIENCES
NeonMind has acquired approximately 18% of TLS, a start-up biotechnology company focused on developing proprietary formulations containing restricted substances such as psilocybin and cannabis.
TLS was engaged to design NeonMind’s psilocybin preclinical research. The TLS team has vast experience designing and conducting preclinical and clinical trials using a restricted substance.
Dr. William Panenka is the founder of TLS as well as a member of NeonMind’s Advisory Board.
CERTARA INC.
Certara ® , the global leader in model-informed drug development was engaged to provide strategic integrated drug development support for the investigation of NeonMind’s psilocybin-based drug candidates for the treatment of obesity.
Certara provides biosimulation software to transform traditional biopharmaceutical R&D with a scientific team that has more than 3,500 years of collective drug discovery and development experience.
Since 2014, 90% of new drug and biologic approvals by the US FDA have beenreceived by Certara’s customers.
CSE: NEON • OTC; NMDBF | 33
-
34
MEDIA COVERAGE
CONFERENCEMay 4 - 5
https://www.psychedelics-conference.com/
PSYCHEDELIC FINANCE INTERVIEWFebruary 2 https://www.psychedelicfinance.com/articles/rob-tessarolo-president-ceo-neonmind-biosciences
REDDIT Q&AFebruary 23
https://www.reddit.com/r/shroomstocks/comments/llazkv/hi_this_is_rob_tessarolo_and_trevor_millar_from/
PSYCHEDELIC SPOTLIGHT Can Psilocybin Cure Obesity? NeonMind Biosciences Thinks it Just Might
https://psychedelicspotlight.com/can-psilocybin-cure-obesity/
NeonMind Takes Psilocybin Therapy Public
https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/
PSYCHEDELICS TODAYPT230 Penny White of NeonMind Biosciences
https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/
THE EYEOPENER: Ryerson professor to lead music-based development program with psychedelic research
https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/
CSE: NEON • OTC: NMDBF | 34
https://psychedelicspotlight.com/can-psilocybin-cure-obesity/https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/